Search results for "P53"

showing 10 items of 303 documents

Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations

1994

The genetics of Wilms' tumour (WT), a paediatric malignancy of the kidney, is complex. Inactivation of the tumour suppressor gene, WT1, is associated with tumour aetiology in approximately 10-15% of WTs. Chromosome 17p changes have been noted in cytogenetic studies of WTs, prompting us to screen 140 WTs for p53 mutations. When histopathology reports were available, p53 mutations were present in eight of eleven anaplastic WTs, a tumour subtype associated with poor prognosis. Amplification of MDM2, a gene whose product binds and sequesters p53, was excluded. Our results indicate that p53 alterations provide a molecular marker for anaplastic WTs.

MaleTumor suppressor geneDNA Mutational AnalysisMolecular Sequence DataGene mutationBiologyMalignancymedicine.disease_causePolymerase Chain ReactionWilms TumorProto-Oncogene ProteinsGeneticsmedicineHumansAmino Acid SequenceGeneAllelesMutationBase SequencefungiNuclear ProteinsCell DifferentiationProto-Oncogene Proteins c-mdm2Wilms' tumorGenes p53Prognosismedicine.diseaseKidney NeoplasmsNeoplasm ProteinsGene Expression Regulation Neoplasticbody regionsGenetic markerbiology.proteinCancer researchMdm2FemaleTumor Suppressor Protein p53Nature Genetics
researchProduct

Anti-aging activity of the Ink4/Arf locus.

2009

The proteins encoded by the Ink4/Arf locus, p16Ink4a, p19Arf and p15Ink4b are major tumour suppressors that oppose aberrant mitogenic signals. The expression levels of the locus are progressively increased during aging and genome-wide association studies have linked the locus to a number of aging-associated diseases and frailty in humans. However, direct measurement of the global impact of the Ink4/Arf locus on organismal aging and longevity was lacking. In this work, we have examined the fertility, cancer susceptibility, aging and longevity of mice genetically modified to carry one (Ink4/Arf-tg) or two (Ink4/Arf-tg/tg) intact additional copies of the locus. First, increased gene dosage of …

Malemedicine.medical_specialtyAgingDNA damageTransgenemedia_common.quotation_subjectLongevityGene DosageLocus (genetics)Mice TransgenicBiologyGene dosagelaw.inventionMicelawInternal medicineNeoplasmsmedicineAnimalsGenes Tumor SuppressorSpermatogenesisGeneCyclin-Dependent Kinase Inhibitor p16Infertility Malemedia_commonCell ProliferationCell growthLongevityCell BiologyImmunity InnateMice Inbred C57BLEndocrinologyCancer researchSuppressorTumor Suppressor Protein p53Aging cell
researchProduct

Prevention of chemotherapy‐induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle

2017

Background Toxicity of chemotherapy on skeletal muscles and the heart may significantly contribute to cancer cachexia, mortality, and decreased quality of life. Doxorubicin (DOX) is an effective cytostatic agent, which unfortunately has toxic effects on many healthy tissues. Blocking of activin receptor type IIB (ACVR2B) ligands is an often used strategy to prevent skeletal muscle loss, but its effects on the heart are relatively unknown. Methods The effects of DOX treatment with or without pre-treatment with soluble ACVR2B-Fc (sACVR2B-Fc) were investigated. The mice were randomly assigned into one of the three groups: (1) vehicle (PBS)-treated controls, (2) DOX-treated mice (DOX), and (3) …

Malep53Cachexialcsh:Diseases of the musculoskeletal systemActivin Receptors Type IILigandsdoxorubicinCcl21lcsh:QM1-695MiceAnimalsHumanssytostaattihoitoMuscle SkeletalAntibiotics AntineoplasticactivinsHeartOriginal Articleslcsh:Human anatomyMyostatinActivinsDoxorubicinmyostatinQuality of LifeOriginal Articleproteiinittranskriptomilcsh:RC925-935TranscriptomelihassurkastumasairaudetJournal of Cachexia, Sarcopenia and Muscle
researchProduct

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

2006

Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas). The mechanism of TMZ-induced glioma cell death is unknown. Here, we show that malignant glioma cells undergo apoptosis following treatment with the methylating agents N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and TMZ. Cell death determined by colony formation and apoptosis following methylation is greatly stimulated by p53. Transfection experiments with O(6)-methylguanine-DNA methyltransferase (MGMT) and depletion of MGMT by O(6)-benzylguanine showed that, in gliomas, the apoptotic signal originates from O(6)-methylguanine (O(6)MeG) and that repair of O(6)MeG by MGMT prevent…

MethylnitronitrosoguanidineCancer ResearchProgrammed cell deathFas Ligand ProteinGuanineDNA repairFas-Associated Death Domain ProteinBlotting WesternApoptosisBiologymedicine.disease_causeO(6)-Methylguanine-DNA MethyltransferaseGliomaTemozolomideTumor Cells CulturedGeneticsmedicineHumansDNA Breaks Double-StrandedRNA Small InterferingAntineoplastic Agents AlkylatingneoplasmsMolecular BiologyTumor Stem Cell AssayCell ProliferationTemozolomideBrain NeoplasmsCell CycleGliomaCell cycleFlow CytometryFas receptormedicine.diseaseDacarbazineProto-Oncogene Proteins c-bcl-2ApoptosisCaspasesCancer researchTumor Suppressor Protein p53CarcinogenesisDNA Damagemedicine.drugOncogene
researchProduct

Apoptosis induced by MNNG in human TK6 lymphoblastoid cells is p53 and Fas/CD95/Apo-1 related.

2003

Agents inducing O(6)-methylguanine (O(6)MeG) in DNA, such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), are not only highly mutagenic and carcinogenic but also cytotoxic because of the induction of apoptosis. In CHO fibroblasts, apoptosis triggered by O(6)MeG requires cell proliferation and MutSalpha-dependent mismatch repair and is related to the induction of DNA double-strand breaks (DSBs). Furthermore, it is mediated by Bcl-2 degradation and does not require p53 for which the cells were mutated [Cancer Res. 60 (2000) 5815]. Here we studied cytotoxicity and apoptosis induced by MNNG in a pair of human lymphoblastoid cells expressing wild-type p53 (TK6) and mutant p53 (WTK1) and show tha…

MethylnitronitrosoguanidineCell SurvivalHealth Toxicology and MutagenesisApoptosisCHO CellsBiologyCell LineBcl-2-associated X proteinCricetinaeProto-Oncogene ProteinsGeneticsCytotoxic T cellAnimalsHumansfas Receptorbcl-2-Associated X ProteinMitogen-Activated Protein Kinase 1Cell growthLymphoblastFas receptorMolecular biologyKineticsCell killingProto-Oncogene Proteins c-bcl-2Cell cultureApoptosisbiology.proteinTumor Suppressor Protein p53DNA DamageMutation research
researchProduct

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

2006

Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme attributed a role in cancer cell resistance to O6-alkylating agent-based chemotherapy. Using a panel of 12 human glioma cell lines, we here defined the sensitivity to TMZ in acute cytotoxicity and clonogenic survival assays in relation to MGMT, mismatch repair and p53 status and its modulation by dexamethasone, irradiation and BCL-X(L). We found that the levels of MGMT expression were a major predictor of T…

MethyltransferaseCell Survivalbcl-X ProteinBcl-xLTransfectionBiochemistryDNA methyltransferaseO(6)-Methylguanine-DNA MethyltransferaseCellular and Molecular NeuroscienceCell Line TumorGliomaTemozolomidemedicineHumansCytotoxicityAntineoplastic Agents AlkylatingneoplasmsTumor Stem Cell AssayTemozolomideCell DeathbiologyGliomamedicine.diseaseCarmustinedigestive system diseasesDacarbazineEnzyme ActivationGene Expression Regulation NeoplasticCancer cellbiology.proteinCancer researchDNA mismatch repairTumor Suppressor Protein p53medicine.drugJournal of Neurochemistry
researchProduct

Establishment and characterization of a nontumorigenic cell line derived from a human hepatocellular adenoma expressing hepatocyte-specific markers.

1997

In the present study the establishment and characterization of a nontumorigenic liver epithelial cell line (HACL-1) derived from a human hepatocellular adenoma is described. The HACL-1 cells have a finite life span (i.e., they proliferate for a period of 2 months and then senesce), show cell-cell contact inhibition, do not grow in soft agar, are not tumorigenic when injected in nude mice, and possess a normal diploid karyotype. The cultured cells resemble hepatocytes, but exhibit some features of dedifferentiation. At the ultrastructural level the cells are endowed with round or oval nuclei, abundant cytoplasmic organelles, and varying amounts of glycogen. The rough endoplasmic reticulum is…

Mice NudeBiologymedicine.disease_causeAdenoma Liver CellCytokeratinMicemedicineBiomarkers TumorTumor Cells CulturedAnimalsHumansCellular SenescenceEndoplasmic reticulumLiver NeoplasmsContact inhibitionEpithelial CellsCell BiologySequence Analysis DNAHepatocellular adenomamedicine.diseaseGenes p53Cell biologymedicine.anatomical_structureCytoplasmCell cultureOrgan SpecificityHepatocyteKaryotypingCarcinogenesisExperimental cell research
researchProduct

Immunohistochemical/histochemical double staining method in the study of the columnar metaplasia of the oesophagus

2014

Intestinal metaplasia in Barrett’s oesophagus (BO) represents an important risk factor for oesophageal adenocarcinoma. Instead, few and controversial data are reported about the progression risk of columnar-lined oesophagus without intestinal metaplasia (CLO), posing an issue about its clinical management. The aim was to evaluate if some immunophenotypic changes were present in CLO independently of the presence of the goblet cells. We studied a series of oesophageal biopsies from patients with endoscopic finding of columnar metaplasia, by performing some immunohistochemical stainings (CK7, p53, AuroraA) combined with histochemistry (Alcian-blue and Alcian/PAS), with the aim of simultaneousl…

Mild Dysplasiap53MalePathologymedicine.medical_specialtyHistologyEsophageal NeoplasmsBiophysicsSettore MED/08 - Anatomia PatologicaBiologyAdenocarcinomadigestive systemBarrett EsophagusEsophagusAntigenMetaplasiamedicineHumansEsophaguslcsh:QH301-705.5Retrospective StudiesMetaplasiaStaining and LabelingBrief ReportBarrett’s oesophagusIntestinal metaplasiaCell Biologymedicine.diseaseImmunohistochemistryEpitheliumdigestive system diseasesBarrett’s oesophagus columnar-lined oesophagus p53 Aurora A kinasemedicine.anatomical_structureBarrett’s oesophagus columnar-lined oesophagus p53 Aurora A kinase.lcsh:Biology (General)columnar-lined oesophagusAdenocarcinomaImmunohistochemistryAurora A kinaseFemaleGoblet Cellsmedicine.symptomEuropean Journal of Histochemistry
researchProduct

Genes, Ageing and Longevity in Humans: Problems, Advantages and Perspectives.

2006

Many epidemiological data indicate the presence of a strong familial component of longevity that is largely determined by genetics, and a number of possible associations between longevity and allelic variants of genes have been described. A breakthrough strategy to get insight into the genetics of longevity is the study of centenarians, the best example of successful ageing. We review the main results regarding nuclear genes as well as the mitochondrial genome, focusing on the investigations performed on Italian centenarians, compared to those from other countries. These studies produced interesting results on many putative "longevity genes". Nevertheless, many discrepancies are reported, l…

Mitochondrial DNAAgingProteasome Endopeptidase ComplexNuclear geneApolipoproteins geneticsInsulin-Like Growth Factor I geneticsmedia_common.quotation_subjectApolipoprotein E4LongevityBiologyGenetic polymorphisms ageing longevity centenarians association studies mitochondrial DNABiochemistryDNA MitochondrialInflammation geneticsApolipoprotein E4 geneticsCytokines geneticsAnimalsHumansAlleleInsulin-Like Growth Factor ILongevity geneticsGenemedia_commonGenetic associationGeneticsAged 80 and overInflammationPolymorphism GeneticAryldialkylphosphataseSuperoxide DismutaseLongevitySuperoxide Dismutase geneticsGeneral MedicineClusterin geneticsPoly(ADP-ribose) Polymerases geneticsAging geneticsApolipoproteinsClusterinTumor Suppressor Protein p53 geneticsGenesEvolutionary biologyTraitCytokinesGene poolPoly(ADP-ribose) PolymerasesTumor Suppressor Protein p53Aryldialkylphosphatase geneticsDNA Mitochondrial geneticsProteasome Endopeptidase Complex physiology
researchProduct

Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm

2020

We have previously shown that the thermolabile, cavity-creating p53 cancer mutant Y220C can be reactivated by small-molecule stabilizers. In our ongoing efforts to unearth druggable variants of the p53 mutome, we have now analyzed the effects of other cancer-associated mutations at codon 220 on the structure, stability, and dynamics of the p53 DNA-binding domain (DBD). We found that the oncogenic Y220H, Y220N, and Y220S mutations are also highly destabilizing, suggesting that they are largely unfolded under physiological conditions. A high-resolution crystal structure of the Y220S mutant DBD revealed a mutation-induced surface crevice similar to that of Y220C, whereas the corresponding pock…

Models Molecular0301 basic medicineMutantCarbazolesDruggabilityCancer therapyAntineoplastic Agents01 natural sciencesBiochemistryDNA-binding proteinStructure-Activity Relationship03 medical and health sciencesProtein DomainsHumansCancer mutationsThermolabileQD0415Protein Stability010405 organic chemistryChemistryArticlesGeneral MedicineSmall moleculeAffinities0104 chemical sciences030104 developmental biologyGene Expression RegulationMutationBiophysicsMolecular MedicineMutant ProteinsDrug Screening Assays AntitumorTumor Suppressor Protein p53CrystallizationProtein BindingQD0241ACS Chemical Biology
researchProduct